# SWOG S8814 (NCT00929591)

> SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

No report yet. It can be ordered.

- Drugs tested: tamoxifen plus CAF
- Indication: postmenopausal endocrine-responsive, node-positive breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00929591
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: SWOG Cancer Research Network
- Conditions: Breast Cancer
- Interventions: cyclophosphamide; doxorubicin hydrochloride; endocrine therapy; endocrine-modulating drug therapy; fluorouracil; tamoxifen citrate; brachytherapy; low-LET electron therapy; low-LET photon therapy; radiation therapy
- Enrollment: 1558
- Primary outcome: Disease-free survival
- Primary outcome: Overall survival
- Primary outcome: Toxicity/morbidity of treatment

## Indexed commentary on SWOG S8814 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 YouTube videos
- 3 podcast episodes

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=swog-s8814-nct00929591